Agenus shared a post on LinkedIn:
“Agenus announces new data at the AACR2026 Annual Meeting, from an investigator-initiated Phase II study evaluating botensilimab + balstilimab (BOT/BAL) in combination with MiNK Therapeutics agenT-797 iNKT cell therapy in PD-1 refractory gastroesophageal (GEC) cancer.
- April 20, 2026
- 2:00–5:00 PM PT / 5:00–8:00 PM ET
- Poster Section 52 | Abstract CT166″
Other articles about AACR2026 on OncoDaily.